Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 139

1.

NOP-Related Mechanisms in Pain and Analgesia.

Toll L, Ozawa A, Cippitelli A.

Handb Exp Pharmacol. 2019 May 22. doi: 10.1007/164_2019_214. [Epub ahead of print]

PMID:
31119465
2.

BU10038 as a safe opioid analgesic with fewer side-effects after systemic and intrathecal administration in primates.

Kiguchi N, Ding H, Cami-Kobeci G, Sukhtankar DD, Czoty PW, DeLoid HB, Hsu FC, Toll L, Husbands SM, Ko MC.

Br J Anaesth. 2019 Jun;122(6):e146-e156. doi: 10.1016/j.bja.2018.10.065. Epub 2019 Mar 1.

PMID:
30916003
3.

Agonist-selective NOP receptor phosphorylation correlates in vitro and in vivo and reveals differential post-activation signaling by chemically diverse agonists.

Mann A, Moulédous L, Froment C, O'Neill PR, Dasgupta P, Günther T, Brunori G, Kieffer BL, Toll L, Bruchas MR, Zaveri NT, Schulz S.

Sci Signal. 2019 Mar 26;12(574). pii: eaau8072. doi: 10.1126/scisignal.aau8072.

PMID:
30914485
4.

Synthesis, Biological Evaluation, and SAR Studies of 14β-phenylacetyl Substituted 17-cyclopropylmethyl-7, 8-dihydronoroxymorphinones Derivatives: Ligands With Mixed NOP and Opioid Receptor Profile.

Kumar V, Polgar WE, Cami-Kobeci G, Thomas MP, Khroyan TV, Toll L, Husbands SM.

Front Psychiatry. 2018 Sep 19;9:430. doi: 10.3389/fpsyt.2018.00430. eCollection 2018.

5.

Influence of neuropathic pain on nicotinic acetylcholine receptor plasticity and behavioral responses to nicotine in rats.

Brunori G, Schoch J, Mercatelli D, Ozawa A, Toll L, Cippitelli A.

Pain. 2018 Nov;159(11):2179-2191. doi: 10.1097/j.pain.0000000000001318.

PMID:
29939964
6.

Analysis of the distribution of spinal NOP receptors in a chronic pain model using NOP-eGFP knock-in mice.

Ozawa A, Brunori G, Cippitelli A, Toll N, Schoch J, Kieffer BL, Toll L.

Br J Pharmacol. 2018 Jul;175(13):2662-2675. doi: 10.1111/bph.14225. Epub 2018 May 6.

PMID:
29582417
7.

Differential regulation of alcohol taking and seeking by antagonism at α4β2 and α3β4 nAChRs.

Cippitelli A, Brunori G, Schoch J, Armishaw CJ, Wu J, Zaveri NT, Giulianotti MA, Welmaker GS, Toll L.

Psychopharmacology (Berl). 2018 Jun;235(6):1745-1757. doi: 10.1007/s00213-018-4883-y. Epub 2018 Mar 23.

8.

Highly Selective and Potent α4β2 nAChR Antagonist Inhibits Nicotine Self-Administration and Reinstatement in Rats.

Wu J, Cippitelli A, Zhang Y, Debevec G, Schoch J, Ozawa A, Yu Y, Liu H, Chen W, Houghten RA, Welmaker GS, Giulianotti MA, Toll L.

J Med Chem. 2017 Dec 28;60(24):10092-10104. doi: 10.1021/acs.jmedchem.7b01250. Epub 2017 Dec 13.

PMID:
29178785
9.

Mu-Opioid receptor biased ligands: A safer and painless discovery of analgesics?

Madariaga-Mazón A, Marmolejo-Valencia AF, Li Y, Toll L, Houghten RA, Martinez-Mayorga K.

Drug Discov Today. 2017 Nov;22(11):1719-1729. doi: 10.1016/j.drudis.2017.07.002. Epub 2017 Jul 22. Review.

PMID:
28743488
10.

Selective κ receptor partial agonist HS666 produces potent antinociception without inducing aversion after i.c.v. administration in mice.

Spetea M, Eans SO, Ganno ML, Lantero A, Mairegger M, Toll L, Schmidhammer H, McLaughlin JP.

Br J Pharmacol. 2017 Aug;174(15):2444-2456. doi: 10.1111/bph.13854. Epub 2017 Jun 27.

11.

In Vitro and In Vivo Profile of PPL-101 and PPL-103: Mixed Opioid Partial Agonist Analgesics with Low Abuse Potential.

Khroyan TV, Cippitelli A, Toll N, Lawson JA, Crossman W, Polgar WE, Toll L.

Front Psychiatry. 2017 Apr 12;8:52. doi: 10.3389/fpsyt.2017.00052. eCollection 2017.

12.

A key role for the N/OFQ-NOP receptor system in modulating nicotine taking in a model of nicotine and alcohol co-administration.

Cippitelli A, Schoch J, Debevec G, Brunori G, Zaveri NT, Toll L.

Sci Rep. 2016 May 20;6:26594. doi: 10.1038/srep26594.

13.

Nociceptin/Orphanin FQ Receptor Structure, Signaling, Ligands, Functions, and Interactions with Opioid Systems.

Toll L, Bruchas MR, Calo' G, Cox BM, Zaveri NT.

Pharmacol Rev. 2016 Apr;68(2):419-57. doi: 10.1124/pr.114.009209. Epub 2016 Mar 8. Review.

14.

Potent μ-Opioid Receptor Agonists from Cyclic Peptides Tyr-c[D-Lys-Xxx-Tyr-Gly]: Synthesis, Biological, and Structural Evaluation.

Li Y, Cazares M, Wu J, Houghten RA, Toll L, Dooley C.

J Med Chem. 2016 Feb 11;59(3):1239-45. doi: 10.1021/acs.jmedchem.5b01899. Epub 2016 Jan 29.

PMID:
26789491
15.

Development and characterization of the α3β4α5 nicotinic receptor cellular membrane affinity chromatography column and its application for on line screening of plant extracts.

Ciesla L, Okine M, Rosenberg A, Dossou KSS, Toll L, Wainer IW, Moaddel R.

J Chromatogr A. 2016 Jan 29;1431:138-144. doi: 10.1016/j.chroma.2015.12.065. Epub 2015 Dec 29.

16.

Direct Phenotypic Screening in Mice: Identification of Individual, Novel Antinociceptive Compounds from a Library of 734,821 Pyrrolidine Bis-piperazines.

Houghten RA, Ganno ML, McLaughlin JP, Dooley CT, Eans SO, Santos RG, LaVoi T, Nefzi A, Welmaker G, Giulianotti MA, Toll L.

ACS Comb Sci. 2016 Jan 11;18(1):51-64. doi: 10.1021/acscombsci.5b00126. Epub 2016 Jan 5.

17.

Varenicline decreases nicotine but not alcohol self-administration in genetically selected Marchigian Sardinian alcohol-preferring (msP) rats.

Scuppa G, Cippitelli A, Toll L, Ciccocioppo R, Ubaldi M.

Drug Alcohol Depend. 2015 Nov 1;156:126-132. doi: 10.1016/j.drugalcdep.2015.09.002. Epub 2015 Sep 8.

18.

Knock-In Mice with NOP-eGFP Receptors Identify Receptor Cellular and Regional Localization.

Ozawa A, Brunori G, Mercatelli D, Wu J, Cippitelli A, Zou B, Xie XS, Williams M, Zaveri NT, Low S, Scherrer G, Kieffer BL, Toll L.

J Neurosci. 2015 Aug 19;35(33):11682-93. doi: 10.1523/JNEUROSCI.5122-14.2015.

19.

High affinity α3β4 nicotinic acetylcholine receptor ligands AT-1001 and AT-1012 attenuate cocaine-induced conditioned place preference and behavioral sensitization in mice.

Khroyan TV, Yasuda D, Toll L, Polgar WE, Zaveri NT.

Biochem Pharmacol. 2015 Oct 15;97(4):531-541. doi: 10.1016/j.bcp.2015.08.083. Epub 2015 Aug 7.

20.

Activation of β2-adrenergic receptor by (R,R')-4'-methoxy-1-naphthylfenoterol inhibits proliferation and motility of melanoma cells.

Wnorowski A, Sadowska M, Paul RK, Singh NS, Boguszewska-Czubara A, Jimenez L, Abdelmohsen K, Toll L, Jozwiak K, Bernier M, Wainer IW.

Cell Signal. 2015 May;27(5):997-1007. doi: 10.1016/j.cellsig.2015.02.012. Epub 2015 Feb 20.

21.

Pharmacological stress is required for the anti-alcohol effect of the α3β4* nAChR partial agonist AT-1001.

Cippitelli A, Brunori G, Gaiolini KA, Zaveri NT, Toll L.

Neuropharmacology. 2015 Jun;93:229-36. doi: 10.1016/j.neuropharm.2015.02.005. Epub 2015 Feb 14.

22.

AT-1001: a high-affinity α3β4 nAChR ligand with novel nicotine-suppressive pharmacology.

Cippitelli A, Wu J, Gaiolini KA, Mercatelli D, Schoch J, Gorman M, Ramirez A, Ciccocioppo R, Khroyan TV, Yasuda D, Zaveri NT, Pascual C, Xie XS, Toll L.

Br J Pharmacol. 2015 Apr;172(7):1834-45. doi: 10.1111/bph.13034. Epub 2015 Jan 23.

23.

BU08073 a buprenorphine analogue with partial agonist activity at μ-receptors in vitro but long-lasting opioid antagonist activity in vivo in mice.

Khroyan TV, Wu J, Polgar WE, Cami-Kobeci G, Fotaki N, Husbands SM, Toll L.

Br J Pharmacol. 2015 Jan;172(2):668-80. doi: 10.1111/bph.12796. Epub 2014 Nov 5.

24.

Tyrosine 308 is necessary for ligand-directed Gs protein-biased signaling of β2-adrenoceptor.

Woo AY, Jozwiak K, Toll L, Tanga MJ, Kozocas JA, Jimenez L, Huang Y, Song Y, Plazinska A, Pajak K, Paul RK, Bernier M, Wainer IW, Xiao RP.

J Biol Chem. 2014 Jul 11;289(28):19351-63. doi: 10.1074/jbc.M114.558882. Epub 2014 May 15.

25.

Discovery of a potent and selective α3β4 nicotinic acetylcholine receptor antagonist from an α-conotoxin synthetic combinatorial library.

Chang YP, Banerjee J, Dowell C, Wu J, Gyanda R, Houghten RA, Toll L, McIntosh JM, Armishaw CJ.

J Med Chem. 2014 Apr 24;57(8):3511-21. doi: 10.1021/jm500183r. Epub 2014 Apr 3.

26.

Challenges for opioid receptor nomenclature: IUPHAR Review 9.

Cox BM, Christie MJ, Devi L, Toll L, Traynor JR.

Br J Pharmacol. 2015 Jan;172(2):317-23. doi: 10.1111/bph.12612. Epub 2014 Jul 1. Review.

27.

The Concise Guide to PHARMACOLOGY 2013/14: overview.

Alexander SP, Benson HE, Faccenda E, Pawson AJ, Sharman JL, McGrath JC, Catterall WA, Spedding M, Peters JA, Harmar AJ; CGTP Collaborators, Abul-Hasn N, Anderson CM, Anderson CM, Araiksinen MS, Arita M, Arthofer E, Barker EL, Barratt C, Barnes NM, Bathgate R, Beart PM, Belelli D, Bennett AJ, Birdsall NJ, Boison D, Bonner TI, Brailsford L, Bröer S, Brown P, Calo G, Carter WG, Catterall WA, Chan SL, Chao MV, Chiang N, Christopoulos A, Chun JJ, Cidlowski J, Clapham DE, Cockcroft S, Connor MA, Cox HM, Cuthbert A, Dautzenberg FM, Davenport AP, Dawson PA, Dent G, Dijksterhuis JP, Dollery CT, Dolphin AC, Donowitz M, Dubocovich ML, Eiden L, Eidne K, Evans BA, Fabbro D, Fahlke C, Farndale R, Fitzgerald GA, Fong TM, Fowler CJ, Fry JR, Funk CD, Futerman AH, Ganapathy V, Gaisnier B, Gershengorn MA, Goldin A, Goldman ID, Gundlach AL, Hagenbuch B, Hales TG, Hammond JR, Hamon M, Hancox JC, Hauger RL, Hay DL, Hobbs AJ, Hollenberg MD, Holliday ND, Hoyer D, Hynes NA, Inui KI, Ishii S, Jacobson KA, Jarvis GE, Jarvis MF, Jensen R, Jones CE, Jones RL, Kaibuchi K, Kanai Y, Kennedy C, Kerr ID, Khan AA, Klienz MJ, Kukkonen JP, Lapoint JY, Leurs R, Lingueglia E, Lippiat J, Lolait SJ, Lummis SC, Lynch JW, MacEwan D, Maguire JJ, Marshall IL, May JM, McArdle CA, McGrath JC, Michel MC, Millar NS, Miller LJ, Mitolo V, Monk PN, Moore PK, Moorhouse AJ, Mouillac B, Murphy PM, Neubig RR, Neumaier J, Niesler B, Obaidat A, Offermanns S, Ohlstein E, Panaro MA, Parsons S, Pwrtwee RG, Petersen J, Pin JP, Poyner DR, Prigent S, Prossnitz ER, Pyne NJ, Pyne S, Quigley JG, Ramachandran R, Richelson EL, Roberts RE, Roskoski R, Ross RA, Roth M, Rudnick G, Ryan RM, Said SI, Schild L, Sanger GJ, Scholich K, Schousboe A, Schulte G, Schulz S, Serhan CN, Sexton PM, Sibley DR, Siegel JM, Singh G, Sitsapesan R, Smart TG, Smith DM, Soga T, Stahl A, Stewart G, Stoddart LA, Summers RJ, Thorens B, Thwaites DT, Toll L, Traynor JR, Usdin TB, Vandenberg RJ, Villalon C, Vore M, Waldman SA, Ward DT, Willars GB, Wonnacott SJ, Wright E, Ye RD, Yonezawa A, Zimmermann M.

Br J Pharmacol. 2013 Dec;170(8):1449-58. doi: 10.1111/bph.12444.

28.

Comparative molecular field analysis of fenoterol derivatives interacting with an agonist-stabilized form of the β₂-adrenergic receptor.

Plazinska A, Pajak K, Rutkowska E, Jimenez L, Kozocas J, Koolpe G, Tanga M, Toll L, Wainer IW, Jozwiak K.

Bioorg Med Chem. 2014 Jan 1;22(1):234-46. doi: 10.1016/j.bmc.2013.11.030. Epub 2013 Nov 23.

29.

Scaffold ranking and positional scanning utilized in the discovery of nAChR-selective compounds suitable for optimization studies.

Wu J, Zhang Y, Maida LE, Santos RG, Welmaker GS, LaVoi TM, Nefzi A, Yu Y, Houghten RA, Toll L, Giulianotti MA.

J Med Chem. 2013 Dec 27;56(24):10103-17. doi: 10.1021/jm401543h. Epub 2013 Dec 12.

30.

[¹²⁵I]AT-1012, a new high affinity radioligand for the α3β4 nicotinic acetylcholine receptors.

Wu J, Perry DC, Bupp JE, Jiang F, Polgar WE, Toll L, Zaveri NT.

Neuropharmacology. 2014 Feb;77:193-9. doi: 10.1016/j.neuropharm.2013.09.023. Epub 2013 Oct 3.

31.

Physical presence of nor-binaltorphimine in mouse brain over 21 days after a single administration corresponds to its long-lasting antagonistic effect on κ-opioid receptors.

Patkar KA, Wu J, Ganno ML, Singh HD, Ross NC, Rasakham K, Toll L, McLaughlin JP.

J Pharmacol Exp Ther. 2013 Sep;346(3):545-54. doi: 10.1124/jpet.113.206086. Epub 2013 Jul 12.

PMID:
23853171
32.

Designing bifunctional NOP receptor-mu opioid receptor ligands from NOP receptor-selective scaffolds. Part I.

Zaveri NT, Jiang F, Olsen C, Polgar WE, Toll L.

Bioorg Med Chem Lett. 2013 Jun 1;23(11):3308-13. doi: 10.1016/j.bmcl.2013.03.101. Epub 2013 Apr 4.

34.

Retrodialysis of N/OFQ into the nucleus accumbens shell blocks cocaine-induced increases in extracellular dopamine and locomotor activity.

Vazquez-DeRose J, Stauber G, Khroyan TV, Xie XS, Zaveri NT, Toll L.

Eur J Pharmacol. 2013 Jan 15;699(1-3):200-6. doi: 10.1016/j.ejphar.2012.11.050. Epub 2012 Dec 5.

35.

Oxidative folding and preparation of α-conotoxins for use in high-throughput structure-activity relationship studies.

Gyanda R, Banerjee J, Chang YP, Phillips AM, Toll L, Armishaw CJ.

J Pept Sci. 2013 Jan;19(1):16-24. doi: 10.1002/psc.2467. Epub 2012 Nov 28.

PMID:
23193084
36.

Sub-anesthetic concentrations of (R,S)-ketamine metabolites inhibit acetylcholine-evoked currents in α7 nicotinic acetylcholine receptors.

Moaddel R, Abdrakhmanova G, Kozak J, Jozwiak K, Toll L, Jimenez L, Rosenberg A, Tran T, Xiao Y, Zarate CA, Wainer IW.

Eur J Pharmacol. 2013 Jan 5;698(1-3):228-34. doi: 10.1016/j.ejphar.2012.11.023. Epub 2012 Nov 23.

37.

Cannabinoid receptor activation correlates with the proapoptotic action of the β2-adrenergic agonist (R,R')-4-methoxy-1-naphthylfenoterol in HepG2 hepatocarcinoma cells.

Paul RK, Ramamoorthy A, Scheers J, Wersto RP, Toll L, Jimenez L, Bernier M, Wainer IW.

J Pharmacol Exp Ther. 2012 Oct;343(1):157-66. doi: 10.1124/jpet.112.195206. Epub 2012 Jul 9.

38.

Rodent motor and neuropsychological behaviour measured in home cages using the integrated modular platform SmartCage™.

Khroyan TV, Zhang J, Yang L, Zou B, Xie J, Pascual C, Malik A, Xie J, Zaveri NT, Vazquez J, Polgar W, Toll L, Fang J, Xie X.

Clin Exp Pharmacol Physiol. 2012 Jul;39(7):614-22. doi: 10.1111/j.1440-1681.2012.05719.x.

39.

Nociceptin/orphanin FQ inhibition with SB612111 ameliorates dextran sodium sulfate-induced colitis.

Alt C, Lam JS, Harrison MT, Kershaw KM, Samuelsson S, Toll L, D'Andrea A.

Eur J Pharmacol. 2012 May 15;683(1-3):285-93. doi: 10.1016/j.ejphar.2012.03.014. Epub 2012 Mar 16.

PMID:
22449384
40.

Thermodynamics and docking of agonists to the β(2)-adrenoceptor determined using [(3)H](R,R')-4-methoxyfenoterol as the marker ligand.

Toll L, Pajak K, Plazinska A, Jozwiak K, Jimenez L, Kozocas JA, Tanga MJ, Bupp JE, Wainer IW.

Mol Pharmacol. 2012 Jun;81(6):846-54. doi: 10.1124/mol.111.077347. Epub 2012 Mar 20.

41.

AT-1001: a high affinity and selective α3β4 nicotinic acetylcholine receptor antagonist blocks nicotine self-administration in rats.

Toll L, Zaveri NT, Polgar WE, Jiang F, Khroyan TV, Zhou W, Xie XS, Stauber GB, Costello MR, Leslie FM.

Neuropsychopharmacology. 2012 May;37(6):1367-76. doi: 10.1038/npp.2011.322. Epub 2012 Jan 25.

42.

Peptides derived from the prohormone proNPQ/spexin are potent central modulators of cardiovascular and renal function and nociception.

Toll L, Khroyan TV, Sonmez K, Ozawa A, Lindberg I, McLaughlin JP, Eans SO, Shahien AA, Kapusta DR.

FASEB J. 2012 Feb;26(2):947-54. doi: 10.1096/fj.11-192831. Epub 2011 Oct 28.

43.

Structural determinants of opioid and NOP receptor activity in derivatives of buprenorphine.

Cami-Kobeci G, Polgar WE, Khroyan TV, Toll L, Husbands SM.

J Med Chem. 2011 Oct 13;54(19):6531-7. doi: 10.1021/jm2003238. Epub 2011 Sep 7.

44.

Differential effects of nociceptin/orphanin FQ (NOP) receptor agonists in acute versus chronic pain: studies with bifunctional NOP/μ receptor agonists in the sciatic nerve ligation chronic pain model in mice.

Khroyan TV, Polgar WE, Orduna J, Montenegro J, Jiang F, Zaveri NT, Toll L.

J Pharmacol Exp Ther. 2011 Nov;339(2):687-93. doi: 10.1124/jpet.111.184663. Epub 2011 Aug 22.

45.

Effect of fenoterol stereochemistry on the β2 adrenergic receptor system: ligand-directed chiral recognition.

Jozwiak K, Plazinska A, Toll L, Jimenez L, Woo AY, Xiao RP, Wainer IW.

Chirality. 2011;23 Suppl 1:E1-6. doi: 10.1002/chir.20963. Epub 2011 May 26. Review.

46.

Orphanin FQ/nociceptin activates nuclear factor kappa B.

Donica CL, Ramirez VI, Awwad HO, Zaveri NT, Toll L, Standifer KM.

J Neuroimmune Pharmacol. 2011 Dec;6(4):617-25. doi: 10.1007/s11481-011-9279-2. Epub 2011 May 6.

47.

Effect of static force on bone conduction hearing thresholds and comfort.

Toll LE, Emanuel DC, Letowski T.

Int J Audiol. 2011 Sep;50(9):632-5. doi: 10.3109/14992027.2011.568013. Epub 2011 Apr 21.

PMID:
21506894
49.

{Beta}2-adrenergic receptor agonists inhibit the proliferation of 1321N1 astrocytoma cells.

Toll L, Jimenez L, Waleh N, Jozwiak K, Woo AY, Xiao RP, Bernier M, Wainer IW.

J Pharmacol Exp Ther. 2011 Feb;336(2):524-32. doi: 10.1124/jpet.110.173971. Epub 2010 Nov 11.

50.

Novel α3β4 nicotinic acetylcholine receptor-selective ligands. Discovery, structure-activity studies, and pharmacological evaluation.

Zaveri N, Jiang F, Olsen C, Polgar W, Toll L.

J Med Chem. 2010 Nov 25;53(22):8187-91. doi: 10.1021/jm1006148. Epub 2010 Oct 27.

Supplemental Content

Support Center